BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BrightGene Bio-Medical Technology readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies BrightGene Bio-Medical Technology
 's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07658560-200@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:BGM0504: Phase 2 readout est. (NCT07658560)
DESCRIPTION:BGM0504\, phase 2\, Obesity.\nStudy: A Study to Evaluate Effica
 cy and Safety of BGM0504 Tablets in Overweight or Obese Participants Witho
 ut Diabetes\nEstimated primary completion: 28 February 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bgm0504#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07658560
URL:https://assetmemo.bio/drug/bgm0504#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07064486-200@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:BGM0504: Phase 3 readout est. (NCT07064486)
DESCRIPTION:BGM0504\, phase 3\, Type 2 Diabetes.\nStudy: A Study of BGM0504
  in Participants With Type 2 Diabetes in Indonesia\nEstimated primary comp
 letion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bgm0504#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07064486
URL:https://assetmemo.bio/drug/bgm0504#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07918625-201@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:BGM1812: Phase 2 readout est. (NCT07918625)
DESCRIPTION:BGM1812\, phase 2\, Obesity.\nStudy: A Study to Evaluate Effica
 cy and Safety of BGM1812 Injection in Overweight or Obese Participants Wit
 hout Diabetes\nEstimated primary completion: 1 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bgm1812#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07918625
URL:https://assetmemo.bio/drug/bgm1812#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743983-200@assetmemo.bio
DTSTAMP:20261121T005028Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:BGM0504: Phase 3 readout est. (NCT07743983)
DESCRIPTION:BGM0504\, phase 3\, Obesity.\nStudy: A Study of BGM0504 in Earl
 y T2DM With Obesity\nEstimated primary completion: 30 September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/bgm0504#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07743983
URL:https://assetmemo.bio/drug/bgm0504#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
